Brief: Biophytis Says First US Patient Enrolled In COVA Study

Biophytis SA

13/10/2020 18:07

Oct 13 (Reuters) - BIOPHYTIS SA  ALBPS.PA :
    * FIRST US PATIENT ENROLLED IN COVA, A MULTINATIONAL PHASE
2/3
CLINICAL TRIAL WITH SARCONEOS (BIO101) FOR THE TREATMENT OF
COVID-19 RELATED RESPIRATORY FAILURE
    * TOTAL OF SEVEN CENTERS OPEN FOR PATIENT RECRUITMENT IN
EUROPE
AND THE AMERICAS
    * RESULTS OF THE COVA TRIAL ARE EXPECTED BEFORE THE END OF
2021,
DEPENDING ON THE EVOLUTION OF THE PANDEMIC

Source text for Eikon:  ID:nNDL3f9wTv 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))